{"analyses":[{"ciLowerLimit":"0.60","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.92","estimateComment":"Based on Cox regression model with Efron's method of tie handling with treatment as a covariate","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","otherAnalysisDescription":"Stratified by macrovascular invasion (Yes vs. No), α-Fetoprotein (ng/mL) (\\< 200 vs. ≥ 200) and region (China vs. ex-China) with all cells that correspond to macrovascular invasion=Yes combined.","pValue":"0.0032","pValueComment":"Log-rank test","paramType":"Hazard Ratio (HR)","paramValue":"0.74","statisticalComment":"Stratified by macrovascular invasion, α-Fetoprotein and region with all cells that correspond to macrovascular invasion=Yes combined","statisticalMethod":"One-sided p-value"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"2.8","value":"2.6"},{"groupId":"OG001","lowerLimit":"1.4","upperLimit":"2.8","value":"2.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"300"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"description":"PFS is the time from randomization to first documented disease progression or death due to any cause per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) based on the Kaplan-Meier method for censored data.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 200 mg pembrolizumab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.","id":"OG000","title":"Pembrolizumab + BSC"},{"description":"Participants received placebo by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.","id":"OG001","title":"Placebo + BSC"}],"paramType":"MEDIAN","populationDescription":"All randomized participants based on the treatment group to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Up to approximately 4 years","title":"Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","type":"SECONDARY","unitOfMeasure":"Months"}